(Lung Cancer) PD-1 Drug Information
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On August 5, Bristol-Myers Squibb announced results from the Phase III CheckMate-026 clinical trial in non-small cell lung cancer. This trial compared Opdivo (nivolumab) with platinum-based chemotherapy, using PFS as the primary endpoint. Unexpectedly, based on PFS, no significant efficacy was demonstrated. All trial participants had detectable PD-L1 levels (currently confirmed: both PD-L1-positive and PD-L1-negative patients showed benefit in second-line treatment, based on the Phase III ONO-4538/BMS-936558 clinical trial).
Bristol-Myers Squibb press release (original)
There is also another PD-1 drug, Keytruda (pembrolizumab). On June 16, Merck announced the KEYNOTE-024 clinical trial results for Keytruda in non-small cell lung cancer patients. Using PFS and overall survival as evaluation criteria, Keytruda compared with conventional chemotherapy (cisplatin and other agents) in initial treatment showed significant efficacy, leading to early termination of the trial. The results were also presented at ASCO 2016 (American Society of Clinical Oncology).
Merck press release (original)
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5